Otonomy, Inc. Logo
Otonomy Announces Presentation of OTO-313 Clinical Results at American Neurotology Society Annual Meeting
April 05, 2021 07:30 ET | Otonomy, Inc.
SAN DIEGO, April 05, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the...
Otonomy, Inc. Logo
Otonomy Announces Multiple Presentations at Association for Research in Otolaryngology Annual Meeting
February 06, 2019 07:30 ET | Otonomy, Inc.
SAN DIEGO, Feb. 06, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced...
Otonomy, Inc. Logo
Otonomy Announces Multiple Presentations at Society for Neuroscience Annual Meeting including OTO-413 Presentation Selected as "Hot Topic"
October 30, 2018 07:30 ET | Otonomy, Inc.
SAN DIEGO, Oct. 30, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced multiple...
Otonomy, Inc. Logo
Otonomy Announces OTIVIDEX™ Data Presentation at American Academy of Otolaryngology - Head and Neck Surgery Foundation Annual Meeting
October 02, 2018 07:30 ET | Otonomy, Inc.
SAN DIEGO, Oct. 02, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced that...
Otonomy, Inc. Logo
Otonomy to Present at Cantor Fitzgerald Global Healthcare Conference
September 25, 2018 16:05 ET | Otonomy, Inc.
SAN DIEGO, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced that...
Otonomy, Inc. Logo
Otonomy Announces OTIPRIO® Co-Promotion Agreement with Mission Pharmacal for Acute Otitis Externa Indication
August 06, 2018 07:30 ET | Otonomy, Inc.
SAN DIEGO, Aug. 06, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced the...
Otonomy, Inc. Logo
Otonomy Initiates Phase 3 Clinical Trial of OTIVIDEX™ in Ménière’s Disease
July 26, 2018 07:30 ET | Otonomy, Inc.
SAN DIEGO, July 26, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced initiation...
Otonomy, Inc. Logo
Otonomy Reports First Quarter 2018 Financial Results and Provides Corporate Update
May 09, 2018 16:20 ET | Otonomy, Inc.
SAN DIEGO, May 09, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today reported financial...
Otonomy, Inc. Logo
Otonomy to Report First Quarter 2018 Financial Results and Provide Corporate Update
May 02, 2018 07:30 ET | Otonomy, Inc.
SAN DIEGO, May 02, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced it will...
Otonomy, Inc. Logo
Otonomy Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update
March 08, 2018 16:24 ET | Otonomy, Inc.
Type C meeting completed with FDA for OTIVIDEX™ in Ménière’s disease Consistent with prior guidance, pivotal trial for OTIVIDEX to start mid-2018 Conference call and webcast today at 4:30 p.m. EST ...